NIKKEI 225
29,258.25 +232.79 (+0.80%) HANG SENG
25,717.67 +307.92 (+1.21%) GOLD FUTURES
1,774.70 +9.00 (+0.51%) DOW
35,258.61 -36.15 (-0.10%) BTC-GBP
45,466.70 +132.83 (+0.29%) CMC Crypto 200
1,462.62 +10.98 (+0.76%)
Biogen Inc. (BIIB)
| Previous close | 281.19 |
| Open | 279.42 |
| Bid | 269.73 x 800 |
| Ask | 269.77 x 800 |
| Day's range | 269.19 - 279.28 |
| 52-week range | 223.25 - 468.55 |
| Volume | 1,496,125 |
| Avg. volume | 956,320 |
| Market cap | 40.609B |
| Beta (5Y monthly) | 0.39 |
| PE ratio (TTM) | 13.98 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Sage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone, an Investigational Two-Week, Once-Daily Therapeutic Being Evaluated for Major Depressive Disorder
CAMBRIDGE, Mass., Jun 15, 2021--Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today announced that the WATERFALL Study in patients with MDD met its primary endpoint with zuranolone (SAGE-217/BIIB125) 50 mg showing statistically significant improvement in depressive symptoms compared with placebo at Day 15 as assessed by the 17-item Hamilton Rating Scale for Depression (HAMD-17) total score. LS means (SE) change from baseline in HAMD-17 total score at Day 15 for patients w
- Business Wire
Sage Therapeutics and Biogen Announce SAGE-324 Phase 2 Placebo-Controlled KINETIC Study in Essential Tremor Met Primary Endpoint
Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today reported topline results from the Phase 2 KINETIC Study evaluating SAGE-324 in the treatment of people with essential tremor (ET). The study (n=67 full analysis set) achieved its primary endpoint of a statistically significant reduction from baseline compared to placebo in The Essential Tremor Rating Assessment Scale (TETRAS) Performance Subscale Item 4 upper limb tremor score on Day 29 (P=0.049), which corresponded to a 36% reduction from baseline in upper limb tremor amplitude in patients receiving SAGE-324 compared to a 21% reduction in patients receiving placebo. Activities of daily living (ADL) scores showed a statistically significant correlation with upper limb tremor score at all timepoints. While not powered to fully examine TETRAS ADL, SAGE-324 was numerically superior to placebo at all time points. Reported treatment-emergent adverse events (TEAEs) were generally consistent with the safety profile of SAGE-324 to date.
- Business Wire
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen, Inc. (BIIB)
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen, Inc. (BIIB)
